Abstract:The discovery of CRISPR/Cas has revolutionized the field of genome editing. CRIPSR/Cas components are part of the bacterial immune system and are able to induce double-strand DNA breaks in the genome, which are resolved by endogenous DNA repair mechanisms. The most relevant of these are the error-prone nonhomologous end joining and homology directed repair pathways. The former can lead to gene knockout by introduction of insertions and deletions at the cut site, while the latter can be used for gene correction based on a provided repair template. In this Account, we focus on the delivery aspects of CRISPR/Cas for therapeutic applications in vivo. Safe and effective delivery of the CRISPR/Cas components into the nucleus of affected cells is essential for therapeutic gene editing. These components can be delivered in several formats, such as pDNA, viral vectors, or ribonuclear complexes. In the ideal case, the delivery system should address the current limitations of CRISPR gene editing, which are (1) lack of targeting specific tissues or cells, (2) the inability to enter cells, (3) activation of the immune system, and (4) off-target events. To circumvent most of these problems, initial therapeutic applications of CRISPR/Cas were performed on cells ex vivo via classical methods (e.g., microinjection or electroporation) and novel methods (e.g., TRIAMF and iTOP). Ideal candidates for such methods are, for example, hematopoietic cells, but not all tissue types are suited for ex vivo manipulation. For direct in vivo application, however, delivery systems are needed that can target the CRISPR/Cas components to specific tissues or cells in the human body, without causing immune activation or causing high frequencies of off-target effects. Viral systems have been used as a first resort to transduce cells in vivo. These systems suffer from problems related to packaging constraints, immunogenicity, and longevity of Cas expression, which favors off-target events. Viral vectors are as such not the best choice for direct in vivo delivery of CRISPR/Cas. Synthetic vectors can deliver nucleic acids as well, without the innate disadvantages of viral vectors. They can be classed into lipid, polymeric, and inorganic particles, all of which have been reported in the literature. The advantage of synthetic systems is that they can deliver the CRISPR/Cas system also as a preformed ribonucleoprotein complex. The transient nature of this approach favors low frequencies of off-target events and minimizes the window of immune activation. Moreover, from a pharmaceutical perspective, synthetic delivery systems are much easier to scale up for clinical use compared to viral vectors and can be chemically functionalized with ligands to obtain target cell specificity. The first preclinical results with lipid nanoparticles delivering CRISPR/Cas either as mRNA or ribonucleoproteins are very promising. The goal is translating these CRISPR/Cas therapeutics to a clinical setting as well. Taken together, these current trends seem to favor the use of sgRNA/Cas ribonucleoprotein complexes delivered in vivo by synthetic particles.

In vivo delivery of functional Cas:DNA nucleoprotein complexes into recipient bacteria through a Type IV Secretion System

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

Cas9 conjugate complex delivering donor DNA for efficient gene editing by homology-directed repair

Enhancing site-specific DNA integration by a Cas9 nuclease fused with a DNA donor-binding domain

Towards sequential conjugation-assisted laboratory evolution (SCALE) of Cas nucleases

Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing

Towards targeted Cas9 (CRISPR‐Cas) delivery: Preparation of IgG antibody‐Cas9 conjugates using a split intein

Programmed genome editing by a miniature CRISPR-Cas12f nuclease

An engineered baculoviral protein and DNA co-delivery system for CRISPR-based mammalian genome editing

Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria

A modular strategy for extracellular vesicle-mediated CRISPR-Cas9 delivery through aptamer-based loading and UV-activated cargo release

CRISPR RNA-guided autonomous delivery of Cas9

Bacterial genome engineering using CRISPR-associated transposases

Self-assembled DNA Nanoclews for the Efficient Delivery of CRISPR-Cas9 for Genome Editing.

Targetron-Assisted Delivery of Exogenous DNA Sequences into Pseudomonas putida through CRISPR-Aided Counterselection

Convergent Arrangement of sgRNA and Cas9 in CRISPRsome for Transcellular Trafficking

CRISPR-Cas9 Delivery to Hard-to-transfect Cells Via Membrane Deformation

Target DNA recognition and cleavage by a reconstituted Type I-G CRISPR-Cas immune effector complex

RNA and DNA Targeting by a Reconstituted Thermus thermophilus Type III-A CRISPR-Cas System